Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing: earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures gives cross-border investors faster access to Tokyo-listed disclosures.
This corporate disclosure from RaQualia Pharma Inc. was processed by Pulse News Wire on May 18, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
TOKYO (Pulse News Wire) — Raqualia Pharma Inc. [4579.T] corrected its dividend result for the fiscal year ending December 2026. The dividend was revised to ¥26.4 from ¥16.9 per share. The correction w
View all RaQualia Pharma Inc. disclosures →
TOKYO (Pulse News Wire) — Raqualia Pharma Inc. [4579.T] corrected its dividend result for the fiscal year ending December 2026.
The dividend was revised to ¥26.4 from ¥16.9 per share. The correction was disclosed on January 18, 2026 after errors were identified in the interim earnings report.
🟢 Confidence: High AI-translated content.